| Naslov: | Remission of chronic urticaria in patients treated with omalizumab |
|---|
| Avtorji: | ID Cvenkel, Klara (Avtor)
ID Bizjak, Mojca, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Šelb, Julij, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Košnik, Mitja, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (537,92 KB)
MD5: FF225E2AD2412145FCAA6A92A630CC70
PDF - Predstavitvena datoteka, prenos (578,75 KB)
MD5: 07A468AB1AD94B9887153B0368726A1D
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | Introduction: This study examined the remission probability and duration in chronic spontaneous urticaria (CSU) patients resistant to second-generation H1-antihistamines (sgAHs) undergoing omalizumab treatment.
Methods: This is a retrospective observational study of 176 adult CSU patients exhibiting a significant pruritus component (≥ 8) of the weekly urticaria activity score (UAS7) despite four daily sgAH tablets and starting omalizumab treatment with 300 mg every 4 weeks. After excluding 13 nonresponders, we analyzed 163 omalizumab responders (mean age 51.8 years, 74.4% female). The intervals between applications were increased. Discontinuation was considered for patients that remained asymptomatic on a gradually reduced dosage (to 150 mg every 12 weeks) without sgAHs.
Results: Omalizumab discontinuation was possible in 25.8% (42/163). The duration of omalizumab treatment before remission ranged from 7 to 6 months. Twenty-one patients (50.0%) maintained complete remission until the end of the observation period (September 2021) for 8 to 68 months. Of the relapsed patients, 71.4% (15/21) effectively controlled CSU with sgAHs. Six patients (28.6%; 6/21) required omalizumab reintroduction after 6 to 40 months of remission, responding favorably.
Conclusions: The study shows that a quarter of severe CSU patients achieve long-term remission. In addition, sgAHs effectively
manage symptoms in a majority of relapsed cases, and those requiring omalizumab reintroduction respond favorably. |
|---|
| Ključne besede: | urticaria, antihistamines, omalizumab, urticaria, remission, urticaria relapse |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 09.01.2024 |
|---|
| Datum sprejetja članka: | 05.05.2024 |
|---|
| Datum objave: | 03.06.2024 |
|---|
| Založnik: | Slovene Welding Society |
|---|
| Leto izida: | 2024 |
|---|
| Št. strani: | str. 59-61 |
|---|
| Številčenje: | Vol. 33, iss. 2 |
|---|
| Izvor: | Acta dermatovenerologica Alpina, Panonica et Adriatica |
|---|
| PID: | 20.500.12556/DiRROS-22659  |
|---|
| UDK: | 616 |
|---|
| ISSN pri članku: | 1318-4458 |
|---|
| DOI: | 10.15570/actaapa.2024.12 |
|---|
| COBISS.SI-ID: | 198342403 |
|---|
| Avtorske pravice: | Authors publishing in our journal retain copyright of their work under the Creative Commons Attribution License (CC BY 4.0). This license allows unrestricted use, distribution, and reproduction of the work in any medium, provided the original author(s) and copyright holder(s) are appropriately credited, and the original publication in the journal is properly cited, following established academic practices. |
|---|
| Opomba: | Soavtorji: Mojca Bizjak, Julij Šelb, Mitja Košnik;
|
|---|
| Datum objave v DiRROS: | 16.06.2025 |
|---|
| Število ogledov: | 405 |
|---|
| Število prenosov: | 233 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
